Cardio-vascular
Refine Search
Generics
USA-based Amneal Pharmaceuticals has announced that it has received Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (FDA) for four generics products. 12 August 2022
Biotechnology
US pharma giant Pfizer has ended its development of PF-07265803, one of the assets it acquired in the $11.4 billion takeover of Array BioPharma in 2019. 5 August 2022
Pharmaceutical
German life sciences major Bayer beat consensus estimates with its sales in the second quarter of 2022, with the 12.82 billion euros ($13 billion) total representing an 18% rise on the same period in 2021. 4 August 2022
Biotechnology
US RNAi therapeutics pioneer Alnylam Pharmaceuticals looked set to close Wednesday’s New York trading with gains in excess of 40%. 3 August 2022
Pharmaceutical
Pfizer has recorded the highest quarterly sales in its history. 28 July 2022
Pharmaceutical
Sanofi has upped its full-year 2022 guidance in presenting the group’s second-quarter financial results. 28 July 2022
Pharmaceutical
US pharma major Bristol Myers Squibb’s (NYSE: BMY) dipped 2% to $73.63 pre-market today, as it released financial results for the second quarter of 2022, which it said reflect continued in-line product growth, strong momentum across the new product portfolio and continued pipeline progress. 27 July 2022
Pharmaceutical
The Johnson & Johnson subsidiary Janssen UK has named Maria Walsh its business unit director, oncology and hematology, cell and gene therapy and pulmonary hypertension. 27 July 2022
Biotechnology
Dutch firm NewAmsterdam Pharma Holding and Frazier Lifesciences Acquisition Corporation, a special purpose acquisition company (SPAC) sponsored by an affiliate of Frazier Healthcare Partners, have agreed to merge. 26 July 2022
Biotechnology
French clinical-stage drug developer Acticor Biotech announced late Thursday that it has received "PRIority Medicines" status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, for the treatment of patients with stroke. 22 July 2022
Generics
Novartis has reported slightly lower than expected revenues for the second quarter, which came in at $12.78 billion, a 1% decline from the same period of last year. 19 July 2022
Generics
Advocate General Juliane Kokott, an adviser to the Court of Justice of the European Union, has urged the court to find that a series of pay-for-delay deals agreed by French drugmaker Servier with generics companies, were anti-competitive. 15 July 2022
Pharmaceutical
German central nervous system (CNS) specialist Neuraxpharm is to buy two product portfolios within its main therapeutic focus area from French vaccines major Sanofi. 12 July 2022
Pharmaceutical
US drugmaker La Jolla Pharmaceuticals Company saw its shares rocket 81.7% to $6.16 in early trading, after it was revealed that it has received a takeover approach from Innoviva. 11 July 2022
Pharmaceutical
Shares in Minneapolis-based DiaMedica Therapeutics, a biopharma focused on developing novel treatments for neurological disorders and kidney diseases, were down by a third in pre-market trading on Thursday. 7 July 2022
Pharmaceutical
French pharma major Sanofi has launched a new non-profit project designed to help at-risk populations in the world’s least developed countries. 4 July 2022
Pharmaceutical
One UK-based company is looking to transform the way metabolic disorders are treated, leveraging many of the same AI-based techniques used to great effect elsewhere. MultiOmic Health chief executive Robert Thong discusses his firm's progress. 4 July 2022
Biotechnology
Japan’s largest drugmaker Takeda has announced late-breaking data from the Phase III SPRING study presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022, demonstrating positive results of Takhzyro (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to 1 July 2022
Pharmaceutical
June 30, 2022
The cardiomyopathies market is set to grow from $1.6 billion in 2021 to $5.2 billion in 2031 across the seven major markets (7MM: USA, 5EU (France, Germany, Italy, Spain, and the UK), and Japan) at a compound annual growth rate (CAGR) of 12.4%. 30 June 2022
Biotechnology
NewAmsterdam Pharma, a Dutch clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, and privately-held Italian Menarini Group have announced an exclusive license agreement for the commercialization of obicetrapib. 29 June 2022
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban. 18 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, under development by Ionis Pharmaceuticals. 4 November 2024
Biotechnology
Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. 4 November 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Pharmaceutical
Denmark-based Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. 28 October 2024
Pharmaceutical
Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. 25 October 2024
Pharmaceutical
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Pharmaceutical
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Pharmaceutical
Johnson & Johnson has reported revenue of $22.5 billion for the third quarter of 2024, a 5.2% increase year-over-year. 15 October 2024
Generics
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Pharmaceutical
Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorable court ruling. 8 October 2024
Pharmaceutical
AstraZeneca has entered into an exclusive license agreement with China’s CSPC Pharmaceutical to advance the development of an early stage, novel small molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. 7 October 2024
Pharmaceutical
Privately-held metabolic health specialist Rivus Pharmaceuticals has announced new clinical data from the Phase IIa HuMAIN study of HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) 1 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze